CA2907668C - Trail enhancers for the selective killing of cancer cells - Google Patents

Trail enhancers for the selective killing of cancer cells Download PDF

Info

Publication number
CA2907668C
CA2907668C CA2907668A CA2907668A CA2907668C CA 2907668 C CA2907668 C CA 2907668C CA 2907668 A CA2907668 A CA 2907668A CA 2907668 A CA2907668 A CA 2907668A CA 2907668 C CA2907668 C CA 2907668C
Authority
CA
Canada
Prior art keywords
compound
trail
pharmaceutically acceptable
acceptable salt
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2907668A
Other languages
English (en)
French (fr)
Other versions
CA2907668A1 (en
Inventor
Vladimir Kravchenko
Richard J. Ulevitch
Kim D. Janda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of CA2907668A1 publication Critical patent/CA2907668A1/en
Application granted granted Critical
Publication of CA2907668C publication Critical patent/CA2907668C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
    • C07D305/12—Beta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2907668A 2013-03-19 2014-03-19 Trail enhancers for the selective killing of cancer cells Active CA2907668C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361803177P 2013-03-19 2013-03-19
US61/803,177 2013-03-19
PCT/US2014/031235 WO2014153415A2 (en) 2013-03-19 2014-03-19 Trail enhancers for the selective killing of cancer cells

Publications (2)

Publication Number Publication Date
CA2907668A1 CA2907668A1 (en) 2014-09-25
CA2907668C true CA2907668C (en) 2021-02-23

Family

ID=51581796

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2907668A Active CA2907668C (en) 2013-03-19 2014-03-19 Trail enhancers for the selective killing of cancer cells

Country Status (8)

Country Link
US (2) US9604950B2 (https=)
EP (1) EP2976076B1 (https=)
JP (1) JP6307149B2 (https=)
KR (2) KR101819874B1 (https=)
CN (1) CN105228618A (https=)
AU (1) AU2014236003A1 (https=)
CA (1) CA2907668C (https=)
WO (1) WO2014153415A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2976076B1 (en) 2013-03-19 2020-03-04 The Scripps Research Institute Trail enhancers for the selective killing of cancer cells
US10195177B2 (en) 2015-10-01 2019-02-05 The University Of Toledo Use of acyl-homoserine lactone derivatives as anti-thrombotic agents
CN105504000B (zh) * 2016-01-21 2019-06-07 福建农林大学 一种筛选n-酰基高丝氨酸内酯类模拟物的方法
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
EP3666908A1 (en) * 2016-06-03 2020-06-17 Institut national de recherche pour l'agriculture, l'alimentation et l'environnement Diet controlled expression of a nucleic acid encoding a pro-apoptotic protein
US12171735B2 (en) 2017-04-19 2024-12-24 Axcess Global Sciences, Llc Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans
CN110935012A (zh) * 2019-12-19 2020-03-31 东北师范大学 一种用于治疗肿瘤的药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924195D0 (en) * 1999-10-13 1999-12-15 Univ Nottingham N-Acyl homoserine lactones for the treatment of cardiac tachyarrhythmias Ischaemic heart disease or congestive heart failure
GB0122914D0 (en) * 2001-09-22 2001-11-14 Univ Nottingham Modulation of stat activity
JP2004231556A (ja) * 2003-01-29 2004-08-19 Nobuhiko Nomura アポトーシス誘導剤
WO2004075839A2 (en) * 2003-02-21 2004-09-10 Irm Llc Methods and compositions for modulating apoptosis
US20070010477A1 (en) * 2005-04-07 2007-01-11 Dolnick Bruce J Acyl homoserine lactones for inhibition of cell growth
WO2007007207A2 (en) * 2005-04-13 2007-01-18 Khairia Youssef Pharmaceutical compositions of 3, 5 -bis (arylidene) -4 -piperidones and analogues there of for modulating cell proliferation
GB0610042D0 (en) * 2006-05-22 2006-06-28 Univ Nottingham Substituted n-acyl homoserine lactones
EP2448930B1 (en) * 2009-07-03 2017-02-15 The National Institute for Biotechnology in the Negev Ltd. N-((S)-2-Oxo-tetrahydro-furan-3-yl)-amide derivatives as inhibitors of the bacterial quorum sensing for treating plant or animal diseases and for preventing the formation of biofilms on medical devices
EP2976076B1 (en) 2013-03-19 2020-03-04 The Scripps Research Institute Trail enhancers for the selective killing of cancer cells

Also Published As

Publication number Publication date
KR101819874B1 (ko) 2018-01-17
US9765061B2 (en) 2017-09-19
KR101743383B1 (ko) 2017-06-02
US20160272603A1 (en) 2016-09-22
CN105228618A (zh) 2016-01-06
US20170101400A1 (en) 2017-04-13
US9604950B2 (en) 2017-03-28
EP2976076A4 (en) 2016-11-16
EP2976076B1 (en) 2020-03-04
JP2016515546A (ja) 2016-05-30
CA2907668A1 (en) 2014-09-25
WO2014153415A3 (en) 2015-01-08
JP6307149B2 (ja) 2018-04-04
WO2014153415A2 (en) 2014-09-25
KR20150135387A (ko) 2015-12-02
KR20170063980A (ko) 2017-06-08
AU2014236003A1 (en) 2015-11-05
EP2976076A2 (en) 2016-01-27

Similar Documents

Publication Publication Date Title
CA2907668C (en) Trail enhancers for the selective killing of cancer cells
JP7032583B2 (ja) アルギナーゼ活性を阻害する組成物及び方法
US20220127257A1 (en) Small molecules
CN109152933B (zh) 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
US20180170862A1 (en) Protein tyrosine phosphatases or shp2 inhibitors and uses thereof
US20190002429A1 (en) Derivatives of Xanthone Compounds
US11377473B2 (en) Albumin-binding prodrugs of auristatin E derivatives
CN105682655A (zh) 抗微生物化合物
GB2467561A (en) Dual calpain-ROS inhibitors
CN106562951B (zh) 一种呋喃类d-3-磷酸甘油酸脱氢酶别构抑制剂及其应用
Wada et al. A specific inhibitory effect of multivalent trehalose toward Aβ (1-40) aggregation
ES2968559T3 (es) Derivados de haloquinolina sustituidos, método de preparación y aplicaciones de los mismos
Liu et al. Novel bioactive hybrid Celecoxib-HDAC Inhibitor, induces apoptosis in human acute lymphoblastic leukemia cells
WO2020006199A2 (en) Methods and agents for modulating inflammation
TW202245804A (zh) 官能化長鏈烴單羧酸及二羧酸及其衍生物以及其於預防或治療疾病之用途
JP2026505827A (ja) 治療剤として使用することができる新規化合物
US20200054593A1 (en) D-3-phosphoglycerate dehydrogenase allosteric inhibitor and use thereof
EP4673139A1 (en) Nbd1 modulators and methods of using the same
Furuishi Biocompatible Choline-and Amino Acid-Based Ionic Liquids: Applications in Pharmaceutical Science
US10519179B2 (en) Highly efficient NRF2 activators-co-releasing molecule hybrids, their use in the treatment of inflammatory or cardiovascular diseases and their process of preparation
TW202440134A (zh) 新穎小分子kras抑制劑：為難成藥標的提供藥物用於癌症治療
JP6281901B2 (ja) 水溶性ポルフィリン誘導体とそれらの製造方法
Garcia-Ruiz et al. 19 Acid Sphingomyelinase, Mitochondria, and

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190415

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240912

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240912

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240912

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251006

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251110

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260120